報價延遲最少15分鐘:2024/12/25 00:48 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
28.3 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-15.87/-1.82
|
|
企業價值
2.14B
|
| 資產負債 |
|
每股賬面淨值
7.05
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
204.00K
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/25 00:48 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |